Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia - PubMed (original) (raw)
. 1999 Sep 15;94(6):2056-64.
Affiliations
- PMID: 10477735
Free article
Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia
T Holyoake et al. Blood. 1999.
Free article
Abstract
Chronic myeloid leukemia (CML) is characterized by an increased proliferative activity of the leukemic progenitors that produce an elevated number of mature granulocytes. Nevertheless, cell cycle-active agents, even in very high doses, are alone unable to eradicate the leukemic clone, suggesting the presence of a rare subset of quiescent leukemic stem cells. To isolate such cells, we first used Hoechst 33342 and Pyronin Y staining to obtain viable G(0) and G(1)/S/G(2)/M fractions of CD34(+) cells by fluorescence-activated cell sorting (FACS) from 6 chronic-phase CML patients' samples and confirmed the quiescent and cycling status of the 2 fractions by demonstration of expected patterns of Ki-67 and D cyclin expression. Leukemic (Ph(+)/BCR-ABL(+)) cells with in vitro progenitor activity and capable of engrafting immunodeficient mice were identified in the directly isolated G(0) cells. Single-cell reverse transcriptase-polymerase chain reaction (RT-PCR) analysis showed that many leukemic CD34(+) G(0) cells also expressed BCR-ABL mRNA. CD34(+) from 8 CML patients were also labeled with carboxyfluorescein diacetate succinimidyl diester (CFSE) before being cultured (with and without added growth factors) to allow viable cells that had remained quiescent (ie, CFSE(+)) after 4 days to be retrieved by FACS. Leukemic progenitors were again detected in all quiescent populations isolated by this second strategy, including those exposed to a combination of flt3-ligand, Steel factor, interleukin-3, interleukin-6, and granulocyte colony-stimulating factor. These findings provide the first direct and definitive evidence of a deeply but reversibly quiescent subpopulation of leukemic cells in patients with CML with both in vitro and in vivo stem cell properties.
Similar articles
- Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.
Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Graham SM, et al. Blood. 2002 Jan 1;99(1):319-25. doi: 10.1182/blood.v99.1.319. Blood. 2002. PMID: 11756187 - Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow.
Leemhuis T, Leibowitz D, Cox G, Silver R, Srour EF, Tricot G, Hoffman R. Leemhuis T, et al. Blood. 1993 Feb 1;81(3):801-7. Blood. 1993. PMID: 7679000 - Differences between normal and CML stem cells: potential targets for clinical exploitation.
Eaves AC, Barnett MJ, Ponchio L, Cashman JD, Petzer AL, Eaves CJ. Eaves AC, et al. Stem Cells. 1998;16 Suppl 1:77-83; discussion 89. doi: 10.1002/stem.5530160809. Stem Cells. 1998. PMID: 11012149 Review. - The biology of normal and neoplastic stem cells in CML.
Eaves C, Udomsakdi C, Cashman J, Barnett M, Eaves A. Eaves C, et al. Leuk Lymphoma. 1993;11 Suppl 1:245-53. doi: 10.3109/10428199309047894. Leuk Lymphoma. 1993. PMID: 8251904 Review.
Cited by
- Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Lee YL, Chen CW, Liu FH, Huang YW, Huang HM. Lee YL, et al. PLoS One. 2013 Apr 17;8(4):e61939. doi: 10.1371/journal.pone.0061939. Print 2013. PLoS One. 2013. PMID: 23613979 Free PMC article. - Lessons to cancer from studies of leukemia and hematopoiesis.
Brown G. Brown G. Front Cell Dev Biol. 2022 Sep 20;10:993915. doi: 10.3389/fcell.2022.993915. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36204679 Free PMC article. Review. - ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma.
Giacalone NJ, Den RB, Eisenberg R, Chen H, Olson SJ, Massion PP, Carbone DP, Lu B. Giacalone NJ, et al. Future Oncol. 2013 May;9(5):737-45. doi: 10.2217/fon.13.19. Future Oncol. 2013. PMID: 23647301 Free PMC article. - Persistence to anti-cancer treatments in the stationary to proliferating transition.
Pearl Mizrahi S, Gefen O, Simon I, Balaban NQ. Pearl Mizrahi S, et al. Cell Cycle. 2016 Dec 16;15(24):3442-3453. doi: 10.1080/15384101.2016.1248006. Epub 2016 Nov 1. Cell Cycle. 2016. PMID: 27801609 Free PMC article. - Right on target: eradicating leukemic stem cells.
Krause DS, Van Etten RA. Krause DS, et al. Trends Mol Med. 2007 Nov;13(11):470-81. doi: 10.1016/j.molmed.2007.09.003. Epub 2007 Nov 5. Trends Mol Med. 2007. PMID: 17981087 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous